Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. more
Time Frame | KPTI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.76% | -0.09% | 0.83% |
1-Month Return | -14.8% | 0.03% | 5.98% |
3-Month Return | 11.53% | -6.26% | 9.65% |
6-Month Return | -14.25% | 1.16% | 14.29% |
1-Year Return | -9.16% | 11.16% | 32.26% |
3-Year Return | -88.17% | 11.98% | 31.61% |
5-Year Return | -95.59% | 47.19% | 94.03% |
10-Year Return | -98.23% | 109.06% | 191.47% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 40.89M | 108.08M | 209.82M | 157.07M | 146.03M | [{"date":"2019-12-31","value":19.49,"profit":true},{"date":"2020-12-31","value":51.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.86,"profit":true},{"date":"2023-12-31","value":69.6,"profit":true}] |
Cost of Revenue | 2.41M | 2.71M | 3.40M | 5.21M | 4.94M | [{"date":"2019-12-31","value":46.17,"profit":true},{"date":"2020-12-31","value":51.89,"profit":true},{"date":"2021-12-31","value":65.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.8,"profit":true}] |
Gross Profit | 38.49M | 105.38M | 206.42M | 151.86M | 141.09M | [{"date":"2019-12-31","value":18.64,"profit":true},{"date":"2020-12-31","value":51.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.57,"profit":true},{"date":"2023-12-31","value":68.35,"profit":true}] |
Gross Margin | 94.11% | 97.50% | 98.38% | 96.68% | 96.62% | [{"date":"2019-12-31","value":95.67,"profit":true},{"date":"2020-12-31","value":99.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.27,"profit":true},{"date":"2023-12-31","value":98.21,"profit":true}] |
Operating Expenses | 227.76M | 277.23M | 304.69M | 294.06M | 270.63M | [{"date":"2019-12-31","value":74.75,"profit":true},{"date":"2020-12-31","value":90.99,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.51,"profit":true},{"date":"2023-12-31","value":88.82,"profit":true}] |
Operating Income | (189.28M) | (171.85M) | (98.27M) | (142.20M) | (129.54M) | [{"date":"2019-12-31","value":-18927500000,"profit":false},{"date":"2020-12-31","value":-17185000000,"profit":false},{"date":"2021-12-31","value":-9827100000,"profit":false},{"date":"2022-12-31","value":-14220200000,"profit":false},{"date":"2023-12-31","value":-12953999900,"profit":false}] |
Total Non-Operating Income/Expense | (20.50M) | (48.43M) | (51.01M) | (45.36M) | (26.98M) | [{"date":"2019-12-31","value":-2050000000,"profit":false},{"date":"2020-12-31","value":-4843400000,"profit":false},{"date":"2021-12-31","value":-5101300000,"profit":false},{"date":"2022-12-31","value":-4535700000,"profit":false},{"date":"2023-12-31","value":-2697900100,"profit":false}] |
Pre-Tax Income | (199.55M) | (195.96M) | (123.82M) | (164.92M) | (142.78M) | [{"date":"2019-12-31","value":-19955000000,"profit":false},{"date":"2020-12-31","value":-19596400000,"profit":false},{"date":"2021-12-31","value":-12382000000,"profit":false},{"date":"2022-12-31","value":-16492200000,"profit":false},{"date":"2023-12-31","value":-14277600000,"profit":false}] |
Income Taxes | 40.00K | 309.00K | 268.00K | 369.00K | 323.00K | [{"date":"2019-12-31","value":10.84,"profit":true},{"date":"2020-12-31","value":83.74,"profit":true},{"date":"2021-12-31","value":72.63,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.53,"profit":true}] |
Income After Taxes | (199.59M) | (196.27M) | (124.09M) | (165.29M) | (143.10M) | [{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-14309900000,"profit":false}] |
Income From Continuous Operations | (199.59M) | (196.27M) | (124.09M) | (165.29M) | (139.77M) | [{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-13976800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (199.59M) | (196.27M) | (124.09M) | (165.29M) | (143.10M) | [{"date":"2019-12-31","value":-19959000000,"profit":false},{"date":"2020-12-31","value":-19627300000,"profit":false},{"date":"2021-12-31","value":-12408800000,"profit":false},{"date":"2022-12-31","value":-16529100000,"profit":false},{"date":"2023-12-31","value":-14309900000,"profit":false}] |
EPS (Diluted) | (3.23) | (2.73) | (1.71) | (2.03) | (1.25) | [{"date":"2019-12-31","value":-323,"profit":false},{"date":"2020-12-31","value":-273,"profit":false},{"date":"2021-12-31","value":-171,"profit":false},{"date":"2022-12-31","value":-203,"profit":false},{"date":"2023-12-31","value":-125,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
KPTI | |
---|---|
Cash Ratio | 2.17 |
Current Ratio | 3.00 |
Quick Ratio | 2.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
KPTI | |
---|---|
ROA (LTM) | -34.27% |
ROE (LTM) | -891.05% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
KPTI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.84 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
KPTI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.67 |
P/B | 12.05 |
Price/FCF | NM |
EV/R | 1.09 |
EV/Ebitda | NM |
PEG | NM |
Karyopharm Therapeutics Inc (KPTI) share price today is $0.7949
Yes, Indians can buy shares of Karyopharm Therapeutics Inc (KPTI) on Vested. To buy Karyopharm Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KPTI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Karyopharm Therapeutics Inc (KPTI) via the Vested app. You can start investing in Karyopharm Therapeutics Inc (KPTI) with a minimum investment of $1.
You can invest in shares of Karyopharm Therapeutics Inc (KPTI) via Vested in three simple steps:
The 52-week high price of Karyopharm Therapeutics Inc (KPTI) is $1.95. The 52-week low price of Karyopharm Therapeutics Inc (KPTI) is $0.62.
The price-to-earnings (P/E) ratio of Karyopharm Therapeutics Inc (KPTI) is
The price-to-book (P/B) ratio of Karyopharm Therapeutics Inc (KPTI) is 12.05
The dividend yield of Karyopharm Therapeutics Inc (KPTI) is 0.00%
The market capitalization of Karyopharm Therapeutics Inc (KPTI) is $101.51M
The stock symbol (or ticker) of Karyopharm Therapeutics Inc is KPTI